These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18343801)

  • 1. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
    Le Pogam S; Seshaadri A; Kosaka A; Chiu S; Kang H; Hu S; Rajyaguru S; Symons J; Cammack N; Nájera I
    J Antimicrob Chemother; 2008 Jun; 61(6):1205-16. PubMed ID: 18343801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
    McCown MF; Rajyaguru S; Le Pogam S; Ali S; Jiang WR; Kang H; Symons J; Cammack N; Najera I
    Antimicrob Agents Chemother; 2008 May; 52(5):1604-12. PubMed ID: 18285474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients.
    Plaza Z; Soriano V; Gonzalez Mdel M; Di Lello FA; Macias J; Labarga P; Pineda JA; Poveda E
    J Antimicrob Chemother; 2011 Dec; 66(12):2838-42. PubMed ID: 21954459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
    Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
    J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5.
    Legrand-Abravanel F; Henquell C; Le Guillou-Guillemette H; Balan V; Mirand A; Dubois M; Lunel-Fabiani F; Payan C; Izopet J
    Antivir Ther; 2009; 14(5):723-30. PubMed ID: 19704176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
    Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
    J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
    Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
    PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.
    Bartels DJ; Sullivan JC; Zhang EZ; Tigges AM; Dorrian JL; De Meyer S; Takemoto D; Dondero E; Kwong AD; Picchio G; Kieffer TL
    J Virol; 2013 Feb; 87(3):1544-53. PubMed ID: 23152524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.
    Jaspe RC; Sulbarán YF; Sulbarán MZ; Loureiro CL; Rangel HR; Pujol FH
    Virol J; 2012 Sep; 9():214. PubMed ID: 22995142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Naturally occurring NS5B variants resistant to non-nucleoside or nucleoside polymerase inhibitors among treatment-naïve hepatitis C patients in south China].
    Li Z; Liu Y; Cai Q; Shao X; Yan Y; Zhao Z
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):653-7. PubMed ID: 26524357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon-Pinson P; Papuchon J; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    J Med Virol; 2014 Aug; 86(8):1350-9. PubMed ID: 24760718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.
    Le Pogam S; Jiang WR; Leveque V; Rajyaguru S; Ma H; Kang H; Jiang S; Singer M; Ali S; Klumpp K; Smith D; Symons J; Cammack N; Nájera I
    Virology; 2006 Aug; 351(2):349-59. PubMed ID: 16713611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
    Jiao P; Xue W; Shen Y; Jin N; Liu H
    Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
    Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.